ReNerve boosts tissue-based products through partnership with Berkeley Biologics

• ReNerve and US-based Berkeley Biologics partner to develop and commercialise two complementary tissue-based product ranges
• First of two new product ranges targeted for Q3 2025 market launch in US and second expected to be launched before year end
• The strategic partnership enhances ReNerve’s suite of surgical solutions in peripheral nerve injury repairs and related surgeries

Special Report: Biotech company ReNerve has inked a strategic partnership with US-based Berkeley Biologics LLC to develop and commercialise two new complementary tissue-based product ranges.

ReNerve (ASX:RNV) said the two product ranges include one that addresses the need for human dermal tissue – deeper layers of the skin often sourced from donors.

The other range meanwhile will provide amniotic tissue products, which are known for their regenerative and healing properties.

Over the coming months, the two companies will look to launch programs for the new product ranges into the US market, which have already been approved, and are set to be produced at Berkeley Biologics’ California facility.

And as part of the partnership, the companies have entered an initial five-year supply agreement for the product ranges, with an ability to extend.

Tapping into a lucrative market

The global dermal and amniotic tissue market was estimated to be worth around US$2.7 billion in 2024 and growing at around 12% CAGR, with the new product ranges used in a host of applications.

The products have uses in the medical procedures that ReNerve seeks to address with its current and future NervAlign range of nerve repair and nerve replacement products.

ReNerve said the products would be a natural extension of its current sales activities, using the same sales network and targeting the same surgeon and hospital customers.

The solutions address multiple surgical applications including trauma and wound care, breast reconstruction, foot and ankle procedures, extremity repairs and orthopaedic and plastic surgeries.

ReNerve noted the products enable surgeons to incorporate additional tissue grafts when treating nerve injuries, addressing both the damaged nerve and underlying trauma.

More from RNV: ReNerve enters high growth Indian market

Building out product offerings

ReNerve plans to launch the first new product line in Q3 2025, with the second reaching market before year-end.

Director Dr Julian Chick said the collaboration with Berkeley Biologics strengthened ReNerve’s position in the surgical tissue market and broadened its offerings to existing customers in the peripheral nerve injury repair space.

“The rationale for this partnership is to build out the product offerings that ReNerve can provide to surgeons, patients and hospitals,” he said.

“The products we are looking to launch this year are used by the existing and new customers for ReNerve’s peripheral nerve product range.

“Surgeons that work on nerve repairs also undertake other types of surgery, where they are required to repair not only damaged nerves.

“With these two new product lines, the company can offer surgeons, hospitals and patients a more complete product range for all the tissues that are required for surgery.”

This article was developed in collaboration with ReNerve, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.